vs

Side-by-side financial comparison of SOLAI Ltd (SLAI) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.

Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $11.0M, roughly 1.1× SOLAI Ltd). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -126.2%, a 376.9% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -43.1%).

SLAI vs SPRO — Head-to-Head

Bigger by revenue
SPRO
SPRO
1.1× larger
SPRO
$12.6M
$11.0M
SLAI
Growing faster (revenue YoY)
SPRO
SPRO
+24123.9% gap
SPRO
24080.8%
-43.1%
SLAI
Higher net margin
SPRO
SPRO
376.9% more per $
SPRO
250.7%
-126.2%
SLAI

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
SLAI
SLAI
SPRO
SPRO
Revenue
$11.0M
$12.6M
Net Profit
$-13.9M
$31.5M
Gross Margin
0.1%
Operating Margin
-126.2%
Net Margin
-126.2%
250.7%
Revenue YoY
-43.1%
24080.8%
Net Profit YoY
-173.4%
250.9%
EPS (diluted)
$-0.01
$0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLAI
SLAI
SPRO
SPRO
Q4 25
$12.6M
Q3 25
$0
Q2 25
$11.0M
$0
Q1 25
$12.0K
Q4 24
$52.0K
Q3 24
$65.0K
Q2 24
$19.4M
$114.0K
Q1 24
$140.0K
Net Profit
SLAI
SLAI
SPRO
SPRO
Q4 25
$31.5M
Q3 25
$-7.4M
Q2 25
$-13.9M
$-1.7M
Q1 25
$-13.9M
Q4 24
Q3 24
$-17.1M
Q2 24
$18.9M
$-17.9M
Q1 24
$-12.7M
Gross Margin
SLAI
SLAI
SPRO
SPRO
Q4 25
Q3 25
Q2 25
0.1%
Q1 25
Q4 24
Q3 24
Q2 24
52.4%
Q1 24
Operating Margin
SLAI
SLAI
SPRO
SPRO
Q4 25
Q3 25
Q2 25
-126.2%
Q1 25
-122758.3%
Q4 24
Q3 24
-28604.6%
Q2 24
-2.6%
-16720.2%
Q1 24
-9987.1%
Net Margin
SLAI
SLAI
SPRO
SPRO
Q4 25
250.7%
Q3 25
Q2 25
-126.2%
Q1 25
-115550.0%
Q4 24
Q3 24
-26380.0%
Q2 24
97.9%
-15668.4%
Q1 24
-9049.3%
EPS (diluted)
SLAI
SLAI
SPRO
SPRO
Q4 25
$0.56
Q3 25
$-0.13
Q2 25
$-0.01
$-0.03
Q1 25
$-0.25
Q4 24
Q3 24
$-0.32
Q2 24
$0.02
$-0.33
Q1 24
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLAI
SLAI
SPRO
SPRO
Cash + ST InvestmentsLiquidity on hand
$1.2M
$40.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$43.8M
$59.0M
Total Assets
$69.1M
$68.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SLAI
SLAI
SPRO
SPRO
Q4 25
$40.3M
Q3 25
$48.6M
Q2 25
$1.2M
$31.2M
Q1 25
$48.9M
Q4 24
$52.9M
Q3 24
$76.3M
Q2 24
$2.3M
$63.5M
Q1 24
$82.3M
Stockholders' Equity
SLAI
SLAI
SPRO
SPRO
Q4 25
$59.0M
Q3 25
$26.5M
Q2 25
$43.8M
$32.8M
Q1 25
$33.8M
Q4 24
$46.1M
Q3 24
$65.5M
Q2 24
$45.9M
$80.5M
Q1 24
$96.2M
Total Assets
SLAI
SLAI
SPRO
SPRO
Q4 25
$68.9M
Q3 25
$54.2M
Q2 25
$69.1M
$62.1M
Q1 25
$77.7M
Q4 24
$110.5M
Q3 24
$135.2M
Q2 24
$63.3M
$149.9M
Q1 24
$167.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SLAI
SLAI
SPRO
SPRO
Operating Cash FlowLast quarter
$-17.0M
$-8.4M
Free Cash FlowOCF − Capex
$-17.0M
FCF MarginFCF / Revenue
-154.2%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-0.26×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SLAI
SLAI
SPRO
SPRO
Q4 25
$-8.4M
Q3 25
$17.4M
Q2 25
$-17.0M
$-17.7M
Q1 25
$-4.0M
Q4 24
$-23.4M
Q3 24
$12.8M
Q2 24
$-12.1M
$-18.7M
Q1 24
$5.9M
Free Cash Flow
SLAI
SLAI
SPRO
SPRO
Q4 25
Q3 25
Q2 25
$-17.0M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
SLAI
SLAI
SPRO
SPRO
Q4 25
Q3 25
Q2 25
-154.2%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
SLAI
SLAI
SPRO
SPRO
Q4 25
Q3 25
Q2 25
0.0%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
SLAI
SLAI
SPRO
SPRO
Q4 25
-0.26×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-0.64×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SLAI
SLAI

Data center$6.5M59%
Cryptocurrency mining$4.6M41%

SPRO
SPRO

Segment breakdown not available.

Related Comparisons